Nav: Home

Medicinal products receiving expedited approval in Europe may not provide intended clinical benefit

September 10, 2019

The majority of marketing authorizations granted through two expedited assessment pathways in Europe are based on non-validated surrogate endpoints rather than clinical outcomes, according to a study published September 10 in the open-access journal PLOS Medicine by Patricia McGettigan of Queen Mary University of London, and colleagues.

The approval of new pharmaceutical products addressing an unmet need or public interest may be speeded up if medicine regulators at the European Medicines Agency agree to assess them through expedited assessment pathways, including conditional marketing authorization (CMA) and accelerated assessment (AA). In the pivotal trials supporting products assessed by expedited pathways, surrogate endpoints (e.g., those based on a blood test or a radiological change) reduce drug development time compared with waiting for the intended clinical outcomes (i.e., benefits in how patients feel or function or how long they survive). However, it is not known how often regulatory approval is based on a surrogate endpoint instead of a clinical outcome, or how accurately the surrogate endpoints used in pivotal trials correspond to improvement in clinical outcomes. To address this gap in knowledge, McGettigan and colleagues used European Public Assessment Reports (EPARs) to identify the primary endpoints in the pivotal trials supporting products authorized through CMA or AA pathways from 2011 through 2018.

Most of the expedited approvals studied (46/51, 90%) were based on surrogate endpoints, none of which has been shown to reliably predict clinical outcomes (i.e., non-validated surrogate endpoints). Among a total of 49 products with surrogate endpoints reported, most were rated as being reasonably likely (n=30, 63%) or of having biological plausibility (n=45, 94%) to predict clinical outcomes. The information provided by the regulator for prescribers and patients did not consistently explain that the approval for the product was based on trials that reported surrogate endpoints rather than clinical outcomes.

The authors note that these findings apply to just two expedited pathways and may not be generalizable to products authorized through the standard pathway. Still, according to the authors, EPARs and summary product characteristic documents, including patient information leaflets, need to state consistently the nature and limitations of endpoints in pivotal trials supporting expedited authorizations so that prescribers and patients appreciate shortcomings in the evidence about actual clinical benefit. For products supported by non-validated surrogate endpoints, postauthorisation measures to confirm clinical benefit should be imposed by the regulator on the marketing authorisation holders.
-end-
Research Article

Funding:

The authors received no specific funding for this work.

Competing Interests:

I have read the journal's policy and the authors of this manuscript have the following competing interests: PM was a seconded national expert with the Pharmacovigilance & Epidemiology Division at the European Medicines Agency from September 1, 2016, until December 31, 2018.

Citation:

Schuster Bruce C, Brhlikova P, Heath J, McGettigan P (2019) The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. PLoS Med 16(9): e1002873. https://doi.org/10.1371/journal.pmed.1002873

Image Credit: DarkoStojanovic, Pixabay

Author Affiliations:

William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom
The Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom
Greater Manchester Mental Health NHS Foundation Trust, Prestwich, Manchester, United Kingdom

In your coverage please use this URL to provide access to the freely available paper: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002873

PLOS

Related Approval Articles:

Alzheimer's experts call for changes in FDA drug approval standards
Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, 'Single Endpoint for New Drug Approvals for Alzheimer's Disease,' urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer's disease.
Nearly 1 in 3 drugs found to have safety concerns after FDA approval
Researchers have found that for drugs approved between 2001 and 2010, nearly 1 in 3 had a postmarket safety event.
Safety events common for pharmaceuticals and biologics after FDA approval
Among more than 200 new pharmaceuticals and biologics approved by the US Food and Drug Administration from 2001 through 2010, nearly a third were affected by a postmarket safety event such as issuance of a boxed warning or safety communication, according to a study published by JAMA.
Don't relax drug approval process, experts warn
Experts are warning that moves to deregulate America's drug approval process could see a flood of unproven and even harmful new drugs enter the market that could threaten human health.
Controversial drug approval stirs deep concerns -- and hope
In September, the Food and Drug Administration approved Exondys, a controversial treatment for Duchenne muscular dystrophy based on tenuous data from just 12 patients.
More Approval News and Approval Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Teaching For Better Humans
More than test scores or good grades — what do kids need to prepare them for the future? This hour, guest host Manoush Zomorodi and TED speakers explore how to help children grow into better humans, in and out of the classroom. Guests include educators Olympia Della Flora and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...